AI Engines For more Details: Perplexity Kagi Labs You
Anticancer Effects: Gemcitabine is effective in treating several types of cancer, including pancreatic cancer, lung cancer, breast cancer, ovarian cancer, and bladder cancer. It works by interfering with the growth and spread of cancer cells in the body.
Cell Cycle Arrest: Gemcitabine disrupts the cell cycle of cancer cells, leading to cell cycle arrest and inhibition of DNA synthesis. This prevents cancer cells from dividing and multiplying.
Apoptosis Induction: Gemcitabine induces apoptosis, or programmed cell death, in cancer cells. By triggering apoptosis, it helps to eliminate cancer cells from the body.
Combination Therapy: Gemcitabine is often used in combination with other chemotherapy drugs or treatments to enhance its effectiveness. Combinations may vary depending on the type and stage of cancer being treated.
Adverse Effects: Common side effects of gemcitabine treatment include nausea, vomiting, diarrhea, fatigue, hair loss (alopecia), mouth sores, decreased appetite, and flu-like symptoms such as fever and chills. These side effects are usually temporary and can often be managed with supportive care.
Bone Marrow Suppression: Gemcitabine can suppress the bone marrow's ability to produce blood cells, leading to decreased levels of white blood cells, red blood cells, and platelets. This can increase the risk of infections, anemia, and bleeding tendencies.
Peripheral Neuropathy: Some individuals may experience peripheral neuropathy, characterized by numbness, tingling, or burning sensations in the hands and feet. This side effect is usually reversible but can persist after treatment cessation in some cases.
Liver and Kidney Function: Gemcitabine may affect liver and kidney function, and periodic monitoring of liver enzymes and kidney function tests may be necessary during treatment.
Infusion Reactions: Rarely, gemcitabine infusion may cause allergic or infusion-related reactions, including fever, chills, rash, and difficulty breathing. These reactions typically occur during or shortly after infusion and require immediate medical attention.
Long-Term Side Effects: Some individuals may experience long-term side effects of gemcitabine treatment, such as secondary cancers, fertility issues, and cognitive changes. These risks should be discussed with a healthcare provider before starting treatment.
Contraindications: Gemcitabine is contraindicated in individuals with a history of severe allergic reactions to the medication or its components. It should be used with caution in individuals with impaired kidney or liver function.
Monitoring: Regular monitoring of blood counts, liver function tests, and kidney function tests is essential during gemcitabine treatment to assess its efficacy and detect any potential adverse effects.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | |
| ADHD | 0.7 | 0.3 | 1.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 1.5 | 0.4 | 2.75 |
| Allergies | 1.2 | 0.8 | 0.5 |
| Allergy to milk products | 0.5 | 0.4 | 0.25 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 0.6 | 0.8 | -0.33 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | |
| Ankylosing spondylitis | 1.5 | 0.6 | 1.5 |
| Anorexia Nervosa | 0.9 | 0.5 | 0.8 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
| Asthma | 0.5 | 0.3 | 0.67 |
| Atherosclerosis | 0.2 | -0.2 | |
| Atrial fibrillation | 1 | 1 | 0 |
| Autism | 3 | 2.4 | 0.25 |
| Autoimmune Disease | 0.3 | 0.2 | 0.5 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| Biofilm | 1 | 1 | |
| Bipolar Disorder | 0.6 | 0.3 | 1 |
| Brain Trauma | 0.3 | 0.3 | |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.6 | -0.6 | |
| Carcinoma | 0.7 | 0.4 | 0.75 |
| Celiac Disease | 0.3 | 0.4 | -0.33 |
| Cerebral Palsy | 0.5 | 0.5 | |
| Chronic Fatigue Syndrome | 1.1 | 1.5 | -0.36 |
| Chronic Kidney Disease | 1 | 0.3 | 2.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 0.6 | 0.17 |
| Chronic Urticaria (Hives) | 0.5 | 0.6 | -0.2 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.3 | 1.33 |
| Cognitive Function | 0.7 | 0.5 | 0.4 |
| Colorectal Cancer | 1.3 | 0.2 | 5.5 |
| Coronary artery disease | 0.9 | 0.3 | 2 |
| COVID-19 | 0.9 | 1.8 | -1 |
| Crohn's Disease | 2.4 | 0.7 | 2.43 |
| deep vein thrombosis | 0.3 | 0.3 | 0 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 1.9 | 1.6 | 0.19 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.1 | 0.5 | 1.2 |
| Endometriosis | 1 | 0.3 | 2.33 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 0.9 | 0.4 | 1.25 |
| erectile dysfunction | 0.8 | 0.8 | |
| Fibromyalgia | 0.6 | 1.2 | -1 |
| Functional constipation / chronic idiopathic constipation | 1.2 | 1.5 | -0.25 |
| gallstone disease (gsd) | 1.2 | 1.2 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
| Generalized anxiety disorder | 1.2 | 0.8 | 0.5 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.3 | 0.5 | -0.67 |
| Graves' disease | 0.4 | 0.6 | -0.5 |
| Gulf War Syndrome | 0.8 | 0.8 | |
| Halitosis | 0.3 | 0.3 | 0 |
| Heart Failure | 1.8 | 1.8 | |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 0.8 | 0.8 | |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
| hyperglycemia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 0.7 | 0.6 | 0.17 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 1.2 | 0.6 | 1 |
| IgA nephropathy (IgAN) | 0.7 | 1.4 | -1 |
| Inflammatory Bowel Disease | 2.1 | 2 | 0.05 |
| Insomnia | 0.6 | 0.3 | 1 |
| Intelligence | 0.5 | 0.6 | -0.2 |
| Intracranial aneurysms | 0.4 | 0.3 | 0.33 |
| Irritable Bowel Syndrome | 1.1 | 1.2 | -0.09 |
| ischemic stroke | 0.7 | 0.7 | |
| Liver Cirrhosis | 1.2 | 0.8 | 0.5 |
| Long COVID | 1.7 | 0.7 | 1.43 |
| Low bone mineral density | 0.3 | -0.3 | |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | 0 |
| ME/CFS with IBS | 0.5 | 0.4 | 0.25 |
| ME/CFS without IBS | 1.1 | 0.6 | 0.83 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.3 | |
| Metabolic Syndrome | 1.8 | 1.2 | 0.5 |
| Mood Disorders | 2.5 | 1.6 | 0.56 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 1.6 | 3 | -0.88 |
| Multiple system atrophy (MSA) | 0.1 | 0.1 | |
| myasthenia gravis | 0.3 | 0.2 | 0.5 |
| neuropathic pain | 0.4 | -0.4 | |
| Neuropathy (all types) | 0.3 | 0.4 | -0.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.1 | 0.3 | 2.67 |
| Obesity | 3 | 1.8 | 0.67 |
| obsessive-compulsive disorder | 0.7 | 1.8 | -1.57 |
| Osteoarthritis | 1.1 | 0.3 | 2.67 |
| Osteoporosis | 0.2 | 0.3 | -0.5 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 1.2 | 1.4 | -0.17 |
| Polycystic ovary syndrome | 2.4 | 0.5 | 3.8 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.5 | -0.67 |
| Primary sclerosing cholangitis | 1 | 2.1 | -1.1 |
| Psoriasis | 0.5 | 1.9 | -2.8 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.2 | 0.5 | 3.4 |
| Rosacea | 0.2 | -0.2 | |
| Schizophrenia | 1.8 | 0.9 | 1 |
| scoliosis | 0.3 | 0.3 | |
| Sjögren syndrome | 1.3 | 0.4 | 2.25 |
| Sleep Apnea | 0.3 | 0.3 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0.8 | |
| Stress / posttraumatic stress disorder | 0.6 | 0.7 | -0.17 |
| Systemic Lupus Erythematosus | 1.8 | 1.8 | |
| Tic Disorder | 0.3 | 0.6 | -1 |
| Tourette syndrome | 0.3 | 0.3 | |
| Type 1 Diabetes | 0.8 | 0.5 | 0.6 |
| Type 2 Diabetes | 1.6 | 1.2 | 0.33 |
| Ulcerative colitis | 1.5 | 1.5 | 0 |
| Unhealthy Ageing | 1.2 | 0.7 | 0.71 |
| Vitiligo | 0.7 | 1 | -0.43 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
